Santhera Pharmaceuticals Holding AG (SANN.SW) is currently considered halal (Sharia-compliant), per In-house ratio engine (last assessed 2026-08-28). See the full ratio breakdown and business-activity screen below for the reasoning.
Computed from Yahoo Finance fundamentals (Tier-4 provider, no filing available), balance sheet as of 2025-12-31. SANN.SW files no SEC reports, so these ratios come from the issuer's own published statements rather than XBRL.
Business activity: cleared (no excluded categories detected)
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 21.80% | 30.00% | Pass |
| Interest-bearing investments | 9.61% | 30.00% | Pass |
| Non-permissible income | 0.53% | 5.00% | Pass |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 34.38% | 33.00% | Fail |
| Interest-bearing investments | 15.15% | 33.00% | Pass |
| Non-liquid assets | 78.97% | at least 20.00% | Pass |
| Non-permissible income | 0.53% | 5.00% | Pass |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 34.38% | 33.33% | Fail |
| Cash + interest-bearing securities | 15.15% | 33.33% | Pass |
| Accounts receivable | 21.03% | 33.33% | Pass |
| Non-permissible income | 0.53% | 5.00% | Pass |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 34.38% | 33.33% | Fail |
| Cash + interest-bearing securities | 15.15% | 33.33% | Pass |
| Accounts receivable | 21.03% | 50.00% | Pass |
| Non-permissible income | 0.53% | 5.00% | Pass |
Scored against a trailing-average market cap (24-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 26.80% | 33.00% | Pass |
| Cash + interest-bearing securities | 11.81% | 33.00% | Pass |
| Accounts receivable | 4.58% | 33.00% | Pass |
| Non-permissible income | 0.53% | 5.00% | Pass |
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 31.29% | 33.00% | Pass |
| Cash + interest-bearing securities | 13.79% | 49.00% | Pass |
| Accounts receivable | 5.35% | 49.00% | Pass |
| Non-permissible income | 0.53% | 5.00% | Pass |
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 31.29% | 33.33% | Pass |
| Cash + interest-bearing securities | 13.79% | 33.33% | Pass |
| Accounts receivable | 19.14% | 49.00% | Pass |
| Non-permissible income | 0.53% | 5.00% | Pass |
Research only, not investment advice. Thresholds are each standard-setter's published limits; a ratio marked “at least” is a floor, not a ceiling.
Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset
Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.
The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally above. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 52.00 | NEUTRAL |
| Stochastic %K (14) | 55.46 | NEUTRAL |
| CCI (20) | 26.38 | NEUTRAL |
| Williams %R (14) | -44.54 | NEUTRAL |
| MACD (12,26,9) | 0.02 | BUY |
| ROC (10) | 2.44 | BUY |
| Momentum (10) | 0.38 | BUY |
| EMA (10) | 15.90 | BUY |
| SMA (10) | 15.71 | BUY |
| EMA (20) | 15.81 | BUY |
| SMA (20) | 15.92 | BUY |
| EMA (30) | 15.74 | BUY |
| SMA (30) | 15.71 | BUY |
| EMA (50) | 15.69 | BUY |
| SMA (50) | 15.45 | BUY |
| EMA (100) | 15.56 | BUY |
| SMA (100) | 15.92 | BUY |
| EMA (200) | 14.59 | BUY |
| SMA (200) | 15.10 | BUY |
Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.
Healthcare · Biotechnology
Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and sells medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the Europe, North America, and Asia. The company's lead pipeline candidate includes Vamorolone, which is developed for the treatments of Duchenne muscular dystrophy. Santhera Pharmaceuticals Holding AG was founded in 2004 and is based in Pratteln, Switzerland.
Background via Yahoo Finance — informational, not part of the verdict.
Peer movement computing — it will appear here on its own.
NO DATA 0 buys · 0 sells
NEUTRAL report date 2026-09-01 · Asset managers net 934180 (-19048)
Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.